What are the top three fundamental stocks?
This is a well-deserved leading stock in precision medicine, leading the vanguard of the industry. With cutting-edge technology and innovative thinking as its cornerstone, it continues to promote medical progress and human health. Its highly specialized team and advanced equipment integrate medical changes into daily practice. The following is a list of the top three stocks in terms of fundamentals, which I hope you like.
What are the top three stocks in terms of fundamentals
The top three stocks in terms of fundamentals are the following three.
1, Myriad Medical: domestic medical device leader. Mainly engaged in medical equipment research and development, manufacturing, marketing and service.
2, Hengrui Medicine: one of the strength of the domestic chemical pharmaceuticals, the most opportunity to challenge the international pharmaceutical giants of Chinese companies. Mainly engaged in drug research and development, production and sales.
3, WuXi AppTec: CRO + CDMO industry chain leader, the world's leading "integrated, end-to-end" new drug R & D service platform. Mainly engaged in the discovery of small molecule chemical drugs, R & D and production of a full range of integrated platform services, in the form of the whole industry chain platform for the global pharmaceutical companies to provide all kinds of new drug development, production and ancillary services, medical device testing and overseas precision medical R & D and production services.
Why Changhong Technology is a medical concept stock
The enterprise is engaged in healthcare-related business. Shenzhen Changhong Mould Technology Co., Ltd. is a limited company registered on April 11, 2001 at the Shenzhen Industrial and Commercial Bureau. Based on the medical and healthcare industry and the precision mold and injection molding industry, Changhong Technology's main businesses include, OA, medical devices, precision medicine and assisted reproduction. The enterprise is a professional precision mold manufacturing as well as injection molding product development and production enterprise group integrating manufacturing and service.
What are the leading precision medicine concept stocks
1. Guilin Sankin (002275): The concept is the most authentic, especially with the U.S. stock market is currently the hottest celator with the most consistent "precision medicine + anti-cancer" concept. Its 100%-owned subsidiary, Baofeng Bio, has been working in the field of precision medicine for many years, and its core research and development personnel are Chinese Americans from large-scale well-known pharmaceutical companies. Baofeng Bio currently has two anti-cancer R&D programs, the Epiduo program (for the treatment of metastatic colorectal cancer) and the Herceptin program (mainly for the treatment of certain HER-2-positive breast cancers), both of which are best-selling anti-cancer drugs.
2. New open source (300109): the fixed-income acquisition of Sanji biological, Heer medical and Jingneng biological 100% equity. Acquisition of companies mainly do genetic testing.
3. Anke Bio (300009): in April 2016, the company intends to 449.88 million yuan to acquire 100% of the equity of Zhongde Meilian. The subject company's business scope includes bioengineering, biochips, genetically engineered antibodies and drugs, etc., belonging to the field of precision medicine.
4. Qianshan Pharmaceutical Machinery (300216): holding subsidiary Hong Hao gene's individualized medication hypertension gene detection chip project
What are the leading stocks of precision medicine
1. Jingfeng Pharmaceuticals: a leading stock of pharmaceuticals. announced on December 21, 2018, the company announced that the company on the company's anti-PD-1 antibody SHR -1210 combined with Apatinib mesylate for the first-line treatment of hepatocellular carcinoma in an international multicenter Phase III clinical trial with the U.S. FDA, which will soon be carried out simultaneously in the United States, Europe and China.
2, Haixiang Pharmaceuticals: leading pharmaceutical stocks. Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. is a listed company held by Guangzhou Pharmaceutical Group Co., Ltd. (A-share 600332, H-share 00874), mainly engaged in, (1) research and development, manufacturing and sales of Chinese and Western patent medicines, chemical raw materials, natural medicines, biomedicine, and intermediates of chemical raw materials and pharmaceuticals; (2) the wholesale, retail, import and export of Western medicines, traditional Chinese medicines and medical devices; (3) the research and development, production and sales of large health products; (4) the development, production and sales of Chinese medicine and medical equipment; (5) the development and sales of Chinese medicine, traditional Chinese medicine and medical equipment. Research and development, manufacture and sale of health products; and (4) investment in health industry such as medical services, health management and health care.
3, China Resources Sanjiu: pharmaceutical leading stocks. 2015 annual pharmaceutical industry profit is expected to 2,602 billion yuan, up 11,9%, the growth rate fell 0,4 percentage points.
4, Kunming Pharmaceutical Group: leading pharmaceutical stocks. The company plans to actively develop the e-commerce industry, expanding to the cell phone APP "State Drug Online", and adding "State Drug Online" channel, to increase the public attention of the State Drug Mall, to cope with the online sale of prescription drugs to loosen the binding, and begin to prepare for the BtoC model. Previously, the company's independently developed and independently operated B2B pharmaceutical e-commerce trading platform, Sinopharm Mall, was formally launched in October 2013, featuring product categories such as pharmaceuticals, food, oral supplies, birth control supplies, medical devices and cosmetics.
5, medicine stone science and technology: pharmaceutical leading stocks. Domestic pharmaceutical outsourcing industry leader, is the first to engage in pharmaceutical R & D production outsourcing CRO and CMO integration of the company, the senior management team *** has more than 200 authorized and applied for patent results; its main business for the discovery of small molecules of chemical drugs, R & D and production of a full range of integrated platform services, in the form of the whole industry chain platform for the global pharmaceutical companies to provide various types of new drug development, production and supporting services. The company also provides medical device testing and overseas precision medical R&D and production services.
What are the non-masked pharmaceutical stocks
1, Jianfan biological (300529): blood perfusion related products stock, China's blood perfusion field leading enterprises. Revenue and net profit for two consecutive years to maintain more than 32% growth, return on net assets of about 24%, gross profit margin of about 84%, dynamic price-earnings ratio of 46 times, the total market value of 24.3 billion.
2, myriad medical (300760): medical equipment leading stocks. Revenue and net profit continued high growth, return on net assets of 28% to 47%, gross profit margin of 66% dynamic price-earnings ratio of 44 times, total market capitalization of 177.1 billion. (Foreign to A-share listing)
3, Pharmacopeia (603259): CRO industry leading stock staring macro. Revenue and net profit continued high growth, return on net assets between 21 a 29%, gross profit margin of 39% or so, dynamic price-earnings ratio of 59 times, total market value of 92.7 billion. (Foreign to hole transport A shares listed)
4, Zhaoyan new drug (603127): 20% or so, gross profit margin of 53% or so pharmaceutical preclinical research service stocks, domestic industry leader in the field of security assessment. Revenue and net profit sustained high growth, return on net assets dynamic price-earnings ratio of 153 times, total market capitalization of 7.3 billion.
5, Aide Bio (300685): tumor precision medicine molecular diagnostics leading stocks. Revenue and net profit for three consecutive years to maintain more than 30% growth, return on net assets of about 20%, Mauna then beam rate of about 91%, dynamic price-earnings ratio of 59 times, total market capitalization of 7.7 billion.
6, OpusCare (300595): the domestic OK lens leading enterprises. Revenue and net profit for many years to maintain more than 30% growth, return on net assets between 21% and 38%, gross profit margin of 77% or so, the dynamic price-earnings ratio of 71 times, total market capitalization of 14.4 billion.
7, Dabo medical (002901): medical high health topic stocks, orthopedic implant class domestic leader. Revenue and net profit for three consecutive years to maintain more than 16% growth, return on net assets of more than 28%, gross profit margin of about 82%, dynamic price-earnings ratio of 40 times, total market capitalization of 13.4 billion.
8, Jianyou shares (603707): pharmaceutical raw materials, preparation stock, the domestic injection of time agent internationalization pioneer enterprises. Revenue and net profit for three consecutive years to maintain more than 32% growth, return on net assets of about 19%, gross profit margin of about 47%, dynamic price-earnings ratio of 31 times, total market value of 19 billion.
9, Dazanlin (603233): South China's leading pharmaceutical chain. Revenue and net profit for two consecutive years to maintain double-digit growth, return on net assets of 18-37% of the dynamic price-earnings ratio of 31 times, total market value of 22.8 billion.
10, Kelaiying (002821): domestic COMO leading enterprises. Revenue and net profit
before the faster growth.